Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
987 questions in 78 reviews · Haematology
current versionsNo studies 256 · 25.9%Ungraded 64 · 6.5%Very low 207 · 21%Low 247 · 25%Moderate 163 · 16.5%High 50 · 5.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
GM‐CSF vs placebo Infections · newly diagnosed patients with myelodysplastic syndromes Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with… (2016) · Cochrane | no estimate extracted | 1 study · 118 participants | Low |
GM‐CSF vs placebo Serious adverse events · newly diagnosed patients with myelodysplastic syndromes Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with… (2016) · Cochrane | no estimate extracted | 2 studies · 149 participants | Low |
GM‐CSF vs placebo Blood transfusions · newly diagnosed patients with myelodysplastic syndromes Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with… (2016) · Cochrane | no estimate extracted | 1 study · 31 participants | Low |
G‐CSF vs placebo Progression‐free survival · newly diagnosed patients with myelodysplastic syndromes Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with… (2016) · Cochrane | no estimate extracted | 1 study · 64 participants | Very low |
G‐CSF vs placebo Time to progression to AML · newly diagnosed patients with myelodysplastic syndromes Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with… (2016) · Cochrane | no estimate extracted | 2 studies · 111 participants | Very low |
G‐CSF vs placebo Quality of life · newly diagnosed patients with myelodysplastic syndromes Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with… (2016) · Cochrane | no estimate extracted | NR | No studies |
G‐CSF vs placebo Infections · newly diagnosed patients with myelodysplastic syndromes Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with… (2016) · Cochrane | no estimate extracted | 2 studies · 167 participants | Very low |
G‐CSF vs placebo Severe adverse events · newly diagnosed patients with myelodysplastic syndromes Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with… (2016) · Cochrane | no estimate extracted | NR | No studies |
G‐CSF vs placebo Blood transfusions · newly diagnosed patients with myelodysplastic syndromes Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with… (2016) · Cochrane | no estimate extracted | 1 study · 64 participants | Very low |
GM‐CSF vs placebo Mortality (12 months · newly diagnosed patients with myelodysplastic syndromes Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with… (2016) · Cochrane | HR 0.88 [0.62, 1.26] | 2 studies · 149 participants | Low |
GM‐CSF vs placebo Progression‐free survival · newly diagnosed patients with myelodysplastic syndromes Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with… (2016) · Cochrane | no estimate extracted | 2 studies · 149 participants | Low |
Intervention NR Overall survival · people diagnosed with chemotherapy‐induced anemia The role of iron in the management of chemotherapy‐induced anemia in cancer patients receiving… (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Hematopoietic response · people diagnosed with chemotherapy‐induced anemia The role of iron in the management of chemotherapy‐induced anemia in cancer patients receiving… (2016) · Cochrane | RR 1.17 [1.09, 1.26] | 7 studies · 1712 participants | High |
Intervention NR Red blood cell transfusion · people diagnosed with chemotherapy‐induced anemia The role of iron in the management of chemotherapy‐induced anemia in cancer patients receiving… (2016) · Cochrane | RR 0.74 [0.6, 0.92] | 7 studies · 1719 participants | Moderate |
Intervention NR Median time to hematopoietic response · people diagnosed with chemotherapy‐induced anemia The role of iron in the management of chemotherapy‐induced anemia in cancer patients receiving… (2016) · Cochrane | HR 0.93 [0.67, 1.28] | 5 studies · 1042 participants | Low |
Intervention NR Mean change in hemoglobin (better indicated by higher values) · people diagnosed with chemotherapy‐induced anemia The role of iron in the management of chemotherapy‐induced anemia in cancer patients receiving… (2016) · Cochrane | MD 0.48 [0.1, 0.86] | 3 studies · 827 participants | Low |
Intervention NR Quality of life (better indicated by higher values) · people diagnosed with chemotherapy‐induced anemia The role of iron in the management of chemotherapy‐induced anemia in cancer patients receiving… (2016) · Cochrane | SMD 0.01 | 3 studies · 1124 participants | High |
Intervention NR Thromboembolic events · people diagnosed with chemotherapy‐induced anemia The role of iron in the management of chemotherapy‐induced anemia in cancer patients receiving… (2016) · Cochrane | RR 0.95 [0.54, 1.65] | 3 studies · 783 participants | Moderate |
Intervention NR Treatment‐related mortality · people diagnosed with chemotherapy‐induced anemia The role of iron in the management of chemotherapy‐induced anemia in cancer patients receiving… (2016) · Cochrane | no estimate extracted | 4 studies · 997 participants | High |
Antifibrinolytics (lysine analogues) vs placebo Number of participants with any bleeding · people with haematological disorders Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders (2016) · Cochrane | no estimate extracted | 1 study · 56 participants | Very low |
Antifibrinolytics (lysine analogues) vs placebo Number of participants with thromboembolism · people with haematological disorders Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders (2016) · Cochrane | no estimate extracted | 2 studies · 68 participants | Very low |
Antifibrinolytics (lysine analogues) vs placebo Mortality (all‐cause) ‐ not reported · people with haematological disorders Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders (2016) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Antifibrinolytics (lysine analogues) vs placebo Number of platelet transfusions per participant ‐ not reported · people with haematological disorders Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders (2016) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Antifibrinolytics (lysine analogues) vs placebo Adverse events of transfusions ‐ not reported · people with haematological disorders Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders (2016) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Antifibrinolytics (lysine analogues) vs placebo Adverse events of antifibrinolytic agents · people with haematological disorders Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders (2016) · Cochrane | no estimate extracted | 2 studies · 74 participants | Very low |
Antifibrinolytics (lysine analogues) vs placebo Quality of life ‐ not reported · people with haematological disorders Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders (2016) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Bortezomib vs no bortezomib Overall Survival · All patients with a diagnosis of multiple myeloma Bortezomib for the treatment of multiple myeloma (2016) · Cochrane | Odds Ratio 0.77 [0.69, 0.86] | 9 studies · 4118 participants | High |
Bortezomib vs no bortezomib Health‐related quality of life · All patients with a diagnosis of multiple myeloma Bortezomib for the treatment of multiple myeloma (2016) · Cochrane | no estimate extracted | 4 studies · 717 participants | Ungraded |
Bortezomib vs no bortezomib Adverse Events: Thrombocytopenia · All patients with a diagnosis of multiple myeloma Bortezomib for the treatment of multiple myeloma (2016) · Cochrane | OR 2.05 [1.7, 2.48] | 8 studies · 3791 participants | Low |
Bortezomib vs no bortezomib Adverse Events: Thrombocytopenia ‐ Bortezomib versus no bortezomib (same background therapy) · All patients with a diagnosis of multiple myeloma Bortezomib for the treatment of multiple myeloma (2016) · Cochrane | OR 1.51 [1.13, 2] | 3 studies · 1196 participants | High |
Bortezomib vs no bortezomib Adverse Events: Thrombocytopenia ‐ Bortezomib versus no bortezomib (different background therapy or other agents) · All patients with a diagnosis of multiple myeloma Bortezomib for the treatment of multiple myeloma (2016) · Cochrane | OR 2.6 [2.01, 3.35] | 5 studies · 2595 participants | Low |
Bortezomib vs no bortezomib Adverse Events: Diarrhoea · All patients with a diagnosis of multiple myeloma Bortezomib for the treatment of multiple myeloma (2016) · Cochrane | OR 2.44 [1.74, 3.43] | 8 studies · 3788 participants | Low |
Bortezomib vs no bortezomib Adverse Events: Diarrhoea ‐ Bortezomib versus no bortezomib (same background therapy) · All patients with a diagnosis of multiple myeloma Bortezomib for the treatment of multiple myeloma (2016) · Cochrane | OR 6.24 [2.79, 13.98] | 4 studies · 1670 participants | Moderate |
Bortezomib vs no bortezomib Adverse Events: Diarrhoea ‐ Bortezomib versus no bortezomib (different background therapy or other agents) · All patients with a diagnosis of multiple myeloma Bortezomib for the treatment of multiple myeloma (2016) · Cochrane | OR 1.8 [1.22, 2.65] | 4 studies · 2118 participants | Moderate |
Bortezomib vs no bortezomib Adverse Events: Peripheral Neuropathy · All patients with a diagnosis of multiple myeloma Bortezomib for the treatment of multiple myeloma (2016) · Cochrane | OR 3.71 [2.92, 4.7] | 10 studies · 4636 participants | Moderate |
Bortezomib vs no bortezomib Adverse Events: Peripheral Neuropathy ‐ Bortezomib versus no bortezomib (same background therapy) · All patients with a diagnosis of multiple myeloma Bortezomib for the treatment of multiple myeloma (2016) · Cochrane | OR 5.1 [3.37, 7.72] | 5 studies · 2040 participants | Low |
Bortezomib vs no bortezomib Adverse Events: Peripheral Neuropathy ‐ Bortezomib versus no bortezomib (different background therapy or other agents) · All patients with a diagnosis of multiple myeloma Bortezomib for the treatment of multiple myeloma (2016) · Cochrane | OR 3.09 [2.3, 4.14] | 5 studies · 2596 participants | High |
Bortezomib vs no bortezomib Overall Survival ‐ Bortezomib versus no bortezomib (same background therapy) · All patients with a diagnosis of multiple myeloma Bortezomib for the treatment of multiple myeloma (2016) · Cochrane | Odds Ratio 0.77 [0.65, 0.92] | 4 studies · 1586 participants | Moderate |
Bortezomib vs no bortezomib Adverse Events: Infections (All) · All patients with a diagnosis of multiple myeloma Bortezomib for the treatment of multiple myeloma (2016) · Cochrane | OR 1.51 [1.27, 1.79] | 9 studies · 4266 participants | Moderate |
Bortezomib vs no bortezomib Adverse Events: Infections (All) ‐ Bortezomib versus no bortezomib (same background therapy) · All patients with a diagnosis of multiple myeloma Bortezomib for the treatment of multiple myeloma (2016) · Cochrane | OR 1.37 [0.97, 1.93] | 4 studies · 1670 participants | High |
Bortezomib vs no bortezomib Adverse Events: Infections (All) ‐ Bortezomib versus no bortezomib (different background therapy or other agents) · All patients with a diagnosis of multiple myeloma Bortezomib for the treatment of multiple myeloma (2016) · Cochrane | OR 1.55 [1.27, 1.9] | 5 studies · 2596 participants | Low |
Bortezomib vs no bortezomib Adverse Events: Cardiac Disorders · All patients with a diagnosis of multiple myeloma Bortezomib for the treatment of multiple myeloma (2016) · Cochrane | OR 1.74 [1.17, 2.58] | 5 studies · 2191 participants | High |
Bortezomib vs no bortezomib Adverse Events: Cardiac Disorders ‐ Bortezomib versus no bortezomib (same background therapy) · All patients with a diagnosis of multiple myeloma Bortezomib for the treatment of multiple myeloma (2016) · Cochrane | OR 1.17 [0.39, 3.52] | 2 studies · 736 participants | Moderate |
Bortezomib vs no bortezomib Adverse Events: Cardiac Disorders ‐ Bortezomib versus no bortezomib (different background therapy or other agents) · All patients with a diagnosis of multiple myeloma Bortezomib for the treatment of multiple myeloma (2016) · Cochrane | OR 1.84 [1.21, 2.81] | 3 studies · 1455 participants | High |
Bortezomib vs no bortezomib Overall Survival ‐ Bortezomib versus no bortezomib (different background therapy or other agents) · All patients with a diagnosis of multiple myeloma Bortezomib for the treatment of multiple myeloma (2016) · Cochrane | Odds Ratio 0.76 [0.67, 0.88] | 5 studies · 2532 participants | High |
Bortezomib vs no bortezomib Progression‐Free Survival · All patients with a diagnosis of multiple myeloma Bortezomib for the treatment of multiple myeloma (2016) · Cochrane | Odds Ratio 0.67 [0.61, 0.72] | 9 studies · 4344 participants | Low |
Bortezomib vs no bortezomib Progression‐Free Survival ‐ Bortezomib versus no bortezomib (same background therapy) · All patients with a diagnosis of multiple myeloma Bortezomib for the treatment of multiple myeloma (2016) · Cochrane | Odds Ratio 0.65 [0.57, 0.74] | 5 studies · 1855 participants | Moderate |
Bortezomib vs no bortezomib Progression‐Free Survival ‐ Bortezomib versus no bortezomib (different background therapy or other agents) · All patients with a diagnosis of multiple myeloma Bortezomib for the treatment of multiple myeloma (2016) · Cochrane | Odds Ratio 0.67 [0.61, 0.75] | 4 studies · 2489 participants | Low |
Bortezomib vs no bortezomib Treatment‐related death · All patients with a diagnosis of multiple myeloma Bortezomib for the treatment of multiple myeloma (2016) · Cochrane | OR 0.76 [0.43, 1.34] | 5 studies · 2389 participants | Low |
Bortezomib vs no bortezomib Treatment‐related death ‐ Bortezomib versus no bortezomib (same background therapy) · All patients with a diagnosis of multiple myeloma Bortezomib for the treatment of multiple myeloma (2016) · Cochrane | OR 0.81 [0.3, 2.16] | 2 studies · 737 participants | Low |